COMMUNIQUÉS West-GlobeNewswire

Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
30/09/2025
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression-Free Survival and Overall Survival FLORHAM PARK, N.J., Sept. 30, 2025 ( [...]
Artelo Biosciences Announces Pricing of $2.0 Million Public Offering
30/09/2025
SOLANA BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]
FDA Clears OsteoProbe® (K250216): First-Ever Device Indication for Measuring Bone Material Strength
30/09/2025
SANTA BARBARA, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Active Life Scientific, Inc. (ALSI), a leader in innovative medical devices for bone quality, today announced that the U.S. Food and Drug Administration (FDA) [...]
STRATA Skin Sciences Receives Continued Validation for its Personalized Approach with New Published Study Highlighting XTRAC® Excimer Laser Treatment Combined with a Topical Drug in Psoriasis
30/09/2025
HORSHAM, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]
Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
30/09/2025
SARASOTA, FL, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery [...]
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting
30/09/2025
BERKELEY, Calif. and MAINZ, Germany, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of [...]
gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms
30/09/2025
ROCKAWAY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer-reviewed study in Frontiers [...]
Medera Strengthens Leadership Team with Three Key Executive Appointments
30/09/2025
Clinical operations, regulatory affairs, technical expertise, and corporate leadership additions support advancing gene therapy pipeline for cardiovascular diseases BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Medera Inc [...]
SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)
30/09/2025
No safety concerns or dose limiting toxicities observed SCY-247 was able to achieve target exposures at doses lower than our first-generation fungerp Safety, tolerability, and pharmacokinetic profile support the [...]
VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology
30/09/2025
Partnership combines Secarna’s OligoCreator® platform with VERAXA’s technology suite to create next-generation targeted therapies for autoimmune and inflammatory diseases ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, [...]
Catheter Precision, Inc. Announces Two New Patents to be Issued by USPTO
30/09/2025
FORT MILL, S.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac [...]
Prenetics Announces CEO Danny Yeung Keynote at Token 2049 Singapore
30/09/2025
- Keynote: “IM8: The World’s Fastest-Growing Supplement Brand Powering Our Bitcoin Treasury - Prenetics currently holds 246 BTC with a NAV of $28M - Prenetics has $63.5m of cash 1 CHARLOTTE, N.C., Sept. 30, 2025 (GLOBE [...]
Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA
30/09/2025
Three Studies Validate BVA-Guided Care Significantly Cuts Hospital Readmissions and Boosts Survival in High-Cost Heart Failure Segments OAK RIDGE, TN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), [...]
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
30/09/2025
VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is the first and only [...]
LifeMD Offers Ozempic® at $499 Per Month through Collaboration with Novo Nordisk
30/09/2025
Ozempic® is now available at this reduced price to eligible self-pay LifeMD patients NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced [...]
AssistRx Joins Second Annual Drug Channels Leadership Forum as Diamond Sponsor
30/09/2025
Invite-only event will address today’s most pressing healthcare system challenges ORLANDO, Fla., Sept. 30, 2025 (GLOBE NEWSWIRE) -- AssistRx , the advanced therapy initiation and patient solutions provider, today [...]
Umoja Biopharma Announces that UB-VV111 Receives FDA Fast Track Designation for Relapsed/Refractory B-Cell Malignancies
30/09/2025
SEATTLE, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Umoja Biopharma, the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, announced today that the U.S. Food and Drug [...]
Reunion Neuroscience Announces First Patient Dosed in REKINDLE Phase 2 Clinical Trial of RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses
30/09/2025
-- AjD Represents an Area of Significant Unmet Need; No U.S. Food and Drug Administration (FDA)-Approved Therapies Available -- -- Following Positive Topline Data in RECONNECT Phase 2 Trial, Expect to Initiate Phase 3 [...]
Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock
30/09/2025
BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq: OCUL) (“Ocular”, the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today [...]

Pages